| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
* Laboratory of Viral Immunology,
Laboratory of Virology,
Rheumatology and Immunology Research Center, Centre Hospitalier de l’Université Laval Research Center (Centre Hospitalier Universitaire de Québec) and Université Laval, Québec, Canada
Human CMV is often associated with transplant rejection and opportunistic infections such as pneumonia in immunosuppressed patients. Current anti-CMV therapies, although effective, show relatively high toxicity, which seriously limits their long-term use. In this study, we provide evidence that leukotriene B4 (LTB4) plays an important role in the fight against murine CMV (MCMV) infection in vivo. Intravenous administration of 50 and 500 ng/kg/day of LTB4 to mice infected with a lethal dose of MCMV significantly increases their survival (50 and 70%, respectively), compared with the placebo-treated group (10% of survival). In mice infected with a sublethal dose of MCMV and treated daily with 50 ng/kg/day of LTB4, the salivary gland viral loads were found to be reduced by 66% compared with the control group. Furthermore, using an allogeneic bone marrow transplantation mouse model, the frequency of MCMV reactivation from latently infected mice was much lower (38%) in LTB4 (500 ng/kg)-treated mice than in the placebo-treated group (78%). Finally, in experiments using 5-lipoxygenase-deficient mice, MCMV viral loads in salivary glands were found to be higher in animals unable to produce leukotrienes than in the control groups, supporting a role of endogenous 5-lipoxygenase products, possibly LTB4, in host defense against CMV infection.
This article has been cited by other articles:
|
|
 |
|
  N. Flamand, M. Luo, M. Peters-Golden, and T. G. Brock Phosphorylation of Serine 271 on 5-Lipoxygenase and Its Role in Nuclear Export J. Biol. Chem., January 2, 2009; 284(1): 306 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gaudreault and J. Gosselin Leukotriene B4 Induces Release of Antimicrobial Peptides in Lungs of Virally Infected Mice J. Immunol., May 1, 2008; 180(9): 6211 - 6221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Liu, H.-E. Claesson, Y. Mahshid, G. Klein, and E. Klein Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures Blood, March 1, 2008; 111(5): 2693 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qiu, K. Straat, A. Rahbar, M. Wan, C. Soderberg-Naucler, and J. Z. Haeggstrom Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells J. Exp. Med., January 21, 2008; 205(1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Haworth and B. D. Levy Endogenous lipid mediators in the resolution of airway inflammation Eur. Respir. J., November 1, 2007; 30(5): 980 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Flamand, M. J. Tremblay, and P. Borgeat Leukotriene B4 Triggers the In Vitro and In Vivo Release of Potent Antimicrobial Agents J. Immunol., June 15, 2007; 178(12): 8036 - 8045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hattermann, S. Picard, M. Borgeat, P. Leclerc, M. Pouliot, and P. Borgeat The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis FASEB J, May 1, 2007; 21(7): 1575 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bozza, F. Bistoni, R. Gaziano, L. Pitzurra, T. Zelante, P. Bonifazi, K. Perruccio, S. Bellocchio, M. Neri, A. M. Iorio, et al. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation Blood, November 15, 2006; 108(10): 3387 - 3396. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
